News

January 29, 2018

29th January 2018, Seattle, United States of America –The Benaroya Research Institute in Seattle announced receipt of National Institute of Health funding to support investigations into the immune mechanisms of PVX108. The research group led by Erik Wambre (PhD) from t...

January 13, 2018

13th January 2018, California, United States of America – Australian biotechnology company Aravax presented preliminary data from the first Phase I clinical trial of its product known as PVX108 at the  Gordon Research Conference on Food Allergy at Ventura Beach in Cali...

January 9, 2018

9th January 2018, California, United States of America – Aravax, an Australian biotechnology company revolutionising peanut allergy treatment, today held the first meeting of its newly appointed Scientific Advisory Board, at the Gordon’s Research Conference on Food All...

Please reload

Archive
Please reload

Aravax


Tel: +61 (0)3 9657 0700
Email: info@aravax.com.au​
Address: Level 9, 31 Queen St

Melbourne, Victoria, 3000

Australia

Contact Us